GreenLight SPAC Presentation Deck

CBH GreenLight's Covid-19 vaccine candidate has strong preclinical performance Comparable preclinical performance to other mRNA vaccines Company GreenLight BIOSCIENCES™ BIONTECH Pfizer moderna UREVAC the RNA peopleⓇ Mouse Neutralizing Ab Titer ~130,000 at 5µg dose Assay: Clinical Isolate -300 at 5µg dose Assay: Pseudovirus ~100 at 1µg dose Assay: Pseudovirus -5120 at 2µg dose Assay: Clinical Isolate CD4 Response ● ● • e ● e ● ● · . ● ● Th1-bias 1.5-3.5% of CD4 T cells producing cytokines Very little Th2 cytokines by ELISA Th1-bias Used ELISpot, not easily compared to flow cytometry Very little Th2 cytokines by ELISA Th1-bias 0.1-0.2% of CD4 T cells producing cytokines No ELISA data Flow data suggests a Th1 bias, but cytokine data suggests a mixed Th1/Th2 response ELISA data does not mirror flow cytometry well 0.2-0.6% of CD4 making Th1 cytokines CD8 Response Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. 5-12.5% of CD8 T cells responding to restimulation by flow cytometry Used a different flow cytometry assay, difficult to compare results. 0.5-1.25% of CD8 T cells responding to restimulation by flow cytometry 5-15% of CD8 T Cells responding to restimulation by flow cytometry Sources: Vogel, A. et al."A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates" (2020); Corbett, K.S., Edwards, D.K., Leist, S.R. et al. Nature (2020); Corbett, K.S. et al. NEJM (2020); Rauch, S. et al. "mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection" (2020); Rauch, S. et al.Nature (2021) HUMAN HEALTH 24

View entire presentation